

Registration No. 333-212363
Registration No. 333-216821
Registration No. 333-223574
Registration No. 333-230116
Registration No. 333-236895
Registration No. 333-253861
Registration No. 333-263555
Registration No. 333-267451
Registration No. 333-270209
Registration No. 333-278250
Registration No. 333-281118

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-212363
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216821
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223574
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230116
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236895
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-253861
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263555
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-267451
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270209
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-278250
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-281118

Under
The Securities Act of 1933

SYROS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

45-3772460
(I.R.S. Employer
Identification Number)

c/o Sonoran Capital Advisors
1733 N Greenfield Road, Suite 104
Mesa, Arizona
(Address of Principal Executive Offices)

85205
(Zip Code)

2012 Equity Incentive Plan
2016 Stock Incentive Plan
2016 Employee Stock Purchase Plan
2022 Equity Incentive Plan
2022 Inducement Stock Incentive Plan
Nonstatutory Stock Option Agreements for Inducement Awards
(Full title of the plan)

Matthew Foster
Chief Restructuring Officer
Syros Pharmaceuticals, Inc.
c/o Sonoran Capital Advisors
1733 N Greenfield Road, Suite 104
Mesa, Arizona 85205
(480) 617-2664
(Name, address, and telephone number, including area code, of agent for service)

Copies to:

Cynthia T. Mazareas, Esq.
Stephanie L. Leopold, Esq.
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement” and collectively, the “Registration Statements”) filed by Syros Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), with the Securities and Exchange Commission (the “SEC”) to deregister any and all shares of the Registrant’s common stock, par value \$0.001 per share (“Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

1. Registration Statement on Form S-8 (File No. 333-212363), filed with the SEC on June 30, 2016, registering 199,925 shares of Common Stock issuable under the Registrant’s 2012 Equity Incentive Plan, as amended, 321,874 shares of Common Stock issuable under the Registrant’s 2016 Stock Incentive Plan (the “2016 Plan”) and 58,666 shares of Common Stock issuable under the Registrant’s 2016 Employee Stock Purchase Plan (the “2016 ESPP”).
2. Registration Statement on Form S-8 (File No. 333-216821), filed with the SEC on March 20, 2017, registering 93,543 shares of Common Stock issuable under the 2016 Plan and 23,385 shares of Common Stock issuable under the 2016 ESPP.
3. Registration Statement on Form S-8 (File No. 333-223574), filed with the SEC on March 12, 2018, registering 105,693 shares of Common Stock issuable under the 2016 Plan and 26,423 shares of Common Stock issuable under the 2016 ESPP.
4. Registration Statement on Form S-8 (File No. 333-230116), filed with the SEC on March 7, 2019, registering 135,063 shares of Common Stock issuable under the 2016 Plan and 33,765 shares of Common Stock issuable under the 2016 ESPP.
5. Registration Statement on Form S-8 (File No. 333-236895), filed with the SEC on March 5, 2020, registering 160,000 shares of Common Stock issuable under the 2016 Plan and 43,367 shares of Common Stock issuable under the 2016 ESPP.
6. Registration Statement on Form S-8 (File No. 333-253861), filed with the SEC on March 4, 2021, registering 160,000 shares of Common Stock issuable under the 2016 Plan and 56,222 shares of Common Stock issuable under the 2016 ESPP.
7. Registration Statement on Form S-8 (File No. 333-263555), filed with the SEC on March 15, 2022, registering 160,000 shares of Common Stock issuable under the 2016 Plan, 62,024 shares of Common Stock issuable under the 2016 ESPP, 100,000 shares of Common Stock issuable under the Registrant’s 2022 Inducement Stock Incentive Plan (the “2022 Inducement Plan”), 36,000 shares of Common Stock issuable to Conley Chee under the Nonstatutory Stock Option Agreement for Inducement Award and 75,000 shares of Common Stock issuable to Jason Haas under the Nonstatutory Stock Option Agreement for Inducement Award.
8. Registration Statement on Form S-8 (File No. 333-267451), filed with the SEC on September 16, 2022, registering 4,737,534 shares of Common Stock issuable under the Registrant’s 2022 Equity Incentive Plan (as amended, the “2022 Plan”).
9. Registration Statement on Form S-8 (File No. 333-270209), filed with the SEC on March 2, 2023, registering 202,631 shares of Common Stock issuable under the 2016 ESPP and 750,000 shares of Common Stock issuable under the 2022 Inducement Plan.
10. Registration Statement on Form S-8 (File No. 333-278250), filed with the SEC on March 27, 2024, registering 32,035 shares of Common Stock issuable under the 2016 ESPP.
11. Registration Statement on Form S-8 (File No. 333-281118), filed with the SEC on July 31, 2024, registering 1,750,000 shares of Common Stock issuable under the 2022 Plan.

All share numbers set forth above reflect a 1-for-10 reverse stock split of Common Stock, that became effective on September 16, 2022.

The Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in Part II of each Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, by filing these Post-Effective Amendments, the Registrant hereby terminates the

effectiveness of the Registration Statements and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statements, if any, as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no securities registered by the Company pursuant to the Registration Statements.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mesa, State of Arizona, on March 10, 2025.

Syros Pharmaceuticals, Inc.

By: /s/ Matthew Foster

Name: Matthew Foster

Title: Chief Restructuring Officer

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.